Conexiant
Login
  • The Analytical Scientist
  • The Cannabis Scientist
  • The Medicine Maker
  • The Ophthalmologist
  • The Pathologist
  • The Traditional Scientist
The Pathologist
  • Explore Pathology

    Explore

    • Latest
    • Insights
    • Case Studies
    • Opinion & Personal Narratives
    • Research & Innovations
    • Product Profiles

    Featured Topics

    • Molecular Pathology
    • Infectious Disease
    • Digital Pathology

    Issues

    • Latest Issue
    • Archive
  • Subspecialties
    • Oncology
    • Histology
    • Cytology
    • Hematology
    • Endocrinology
    • Neurology
    • Microbiology & Immunology
    • Forensics
    • Pathologists' Assistants
  • Training & Education

    Career Development

    • Professional Development
    • Career Pathways
    • Workforce Trends

    Educational Resources

    • Guidelines & Recommendations
    • App Notes

    Events

    • Webinars
    • Live Events
  • Events
    • Live Events
    • Webinars
  • Profiles & Community

    People & Profiles

    • Power List
    • Voices in the Community
    • Authors & Contributors
  • Multimedia
    • Video
    • Podcasts
Subscribe
Subscribe

False

The Pathologist / Issues / 2016 / Apr / Cells on the (Invasion) Front Lines
Oncology Oncology Cytology Biochemistry and molecular biology Molecular Pathology

Cells on the (Invasion) Front Lines

Long thought to be a key component of the metastatic process, researchers are now questioning long-held beliefs of the role of epithelial-to-mesenchymal transition

By Michael Schubert, Shyamala Maheswaran, Dingcheng Gao 04/22/2016 1 min read

Share

The diagnosis and treatment of cancer has moved ahead by leaps and bounds – except when it comes to metastatic disease. Cancer that has spread beyond its origins remains the leading cause of death from the disease, according to the World Health Organization, and although it’s a major focus of research, we know little more about its mechanisms today than we did a decade or more ago. This is especially true when it comes to the epithelial-to-mesenchymal transition (EMT), a key component of the metastatic process… or is it?

The debate over EMT’s significance in cancer spreading is a fierce and ongoing one, largely due to the difficulties inherent in observing and understanding it. Why are researchers so convinced of EMT’s role in metastasis? It’s well known that mesenchymal cells are more capable of escaping the primary tumor, and of taking up residence in distant sites. But the evidence against EMT-driven metastasis is mounting, too – most cells in metastatic lesions exhibit epithelial, not mesenchymal, characteristics. Some scientists refer to the reverse process, mesenchymal-to-epithelial transition (MET) to explain this behavior, but others aren’t so sure. At the root of the confusion is a lack of evidence. Until the entire metastatic process – local invasion, intravasation, circulation, arrest and extravasation, proliferation, and angiogenesis – is observed in mesenchymal cells, the role of EMT in metastasis remains an open question. Despite the debate, many researchers simply take EMT’s role in metastasis as read. Searching the PubMed database for “EMT and metastasis” brings up 3,675 publications, and even Wikipedia – the first port of call for most non-experts without access to peer-reviewed articles – boldly states, “EMT and MET form the initiation and completion of the invasion-metastasis cascade.” There’s little indication of doubt, and yet, recent studies are threatening to completely overhaul the research community’s view of EMT and metastasis. Exactly how do these two aspects of cancer biology interact? The quest to understand is more intense than ever, thanks to groundbreaking new data from research groups whose conclusions go against the grain.

PROCEED WITH CAUTION

TRACKING THE TRANSITION

THE PDAC KEY

RESEARCH TIMELINE

Newsletters

Receive the latest pathology news, personalities, education, and career development – weekly to your inbox.

Newsletter Signup Image

About the Author(s)

Michael Schubert

While obtaining degrees in biology from the University of Alberta and biochemistry from Penn State College of Medicine, I worked as a freelance science and medical writer. I was able to hone my skills in research, presentation and scientific writing by assembling grants and journal articles, speaking at international conferences, and consulting on topics ranging from medical education to comic book science. As much as I’ve enjoyed designing new bacteria and plausible superheroes, though, I’m more pleased than ever to be at Texere, using my writing and editing skills to create great content for a professional audience.

More Articles by Michael Schubert

Shyamala Maheswaran

Associate Professor of Surgery at Harvard Medical School and Assistant Molecular Biologist at the Center for Cancer Research, Massachusetts General Hospital, Boston, USA.

More Articles by Shyamala Maheswaran

Dingcheng Gao

Dingcheng Gao is Assistant Professor of Cell and Developmental Biology in Cardiothoracic Surgery at Weill Cornell Medical College, New York, USA.

More Articles by Dingcheng Gao

Explore More in Pathology

Dive deeper into the world of pathology. Explore the latest articles, case studies, expert insights, and groundbreaking research.

False

Advertisement

Recommended

False

False

The Pathologist
Subscribe

About

  • About Us
  • Work at Conexiant Europe
  • Terms and Conditions
  • Privacy Policy
  • Advertise With Us
  • Contact Us

Copyright © 2025 Texere Publishing Limited (trading as Conexiant), with registered number 08113419 whose registered office is at Booths No. 1, Booths Park, Chelford Road, Knutsford, England, WA16 8GS.